Literature DB >> 27268286

Combinatorial strategies for combating invasive fungal infections.

Michaela Spitzer1, Nicole Robbins1, Gerard D Wright1.   

Abstract

Invasive fungal infections are an important cause of human mortality and morbidity, particularly for immunocompromised populations. However, there remains a paucity of antifungal drug treatments available to combat these fungal pathogens. Further, antifungal compounds are plagued with problems such as host toxicity, fungistatic activity, and the emergence of drug resistance in pathogen populations. A promising therapeutic strategy to increase drug effectiveness and mitigate the emergence of drug resistance is through the use of combination drug therapy. In this review we describe the current arsenal of antifungals in medicine and elaborate on the benefits of combination therapy to expand our current antifungal drug repertoire. We examine those antifungal combinations that have shown potential against fungal pathogens and discuss strategies being employed to discover novel combination therapeutics, in particular combining antifungal agents with non-antifungal bioactive compounds. The findings summarized in this review highlight the promise of combinatorial strategies in combatting invasive mycoses.

Entities:  

Keywords:  Aspergillus; Candida; Cryptococcus; antifungal; combination therapy; drug synergy

Mesh:

Substances:

Year:  2016        PMID: 27268286      PMCID: PMC5354157          DOI: 10.1080/21505594.2016.1196300

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  144 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Functional classification of drugs by properties of their pairwise interactions.

Authors:  Pamela Yeh; Ariane I Tschumi; Roy Kishony
Journal:  Nat Genet       Date:  2006-03-19       Impact factor: 38.330

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus.

Authors:  Frédéric Lamoth; Praveen R Juvvadi; Christopher Gehrke; Yohannes G Asfaw; William J Steinbach
Journal:  J Infect Dis       Date:  2013-10-04       Impact factor: 5.226

5.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

6.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

7.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.

Authors:  Leah E Cowen; Sheena D Singh; Julia R Köhler; Cathy Collins; Aimee K Zaas; Wiley A Schell; Hamza Aziz; Eleftherios Mylonakis; John R Perfect; Luke Whitesell; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

8.  A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.

Authors:  Arthur T Jackson; Jesse C Nussbaum; Jacob Phulusa; Dan Namarika; Maria Chikasema; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Charles van der Horst; Thomas S Harrison
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

9.  Advancing the development of tuberculosis therapy.

Authors:  Alimuddin Zumla; Richard Hafner; Christian Lienhardt; Michael Hoelscher; Andrew Nunn
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

10.  ASDCD: antifungal synergistic drug combination database.

Authors:  Xing Chen; Biao Ren; Ming Chen; Ming-Xi Liu; Wei Ren; Quan-Xin Wang; Li-Xin Zhang; Gui-Ying Yan
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

View more
  47 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 2.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

3.  The unmet clinical need of novel antifungal drugs.

Authors:  Damian J Krysan
Journal:  Virulence       Date:  2017-02-17       Impact factor: 5.882

4.  Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2.

Authors:  Tavia Caplan; Álvaro Lorente-Macías; Peter J Stogios; Elena Evdokimova; Sabrina Hyde; Melanie A Wellington; Sean Liston; Kali R Iyer; Emily Puumala; Tanvi Shekhar-Guturja; Nicole Robbins; Alexei Savchenko; Damian J Krysan; Luke Whitesell; William J Zuercher; Leah E Cowen
Journal:  Cell Chem Biol       Date:  2020-01-07       Impact factor: 8.116

Review 5.  Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).

Authors:  Edinaira Sulany Oliveira de Sousa; Ana Claúdia Alves Cortez; Marcia de Souza Carvalho Melhem; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-08-05       Impact factor: 2.476

6.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species.

Authors:  Shahram Mahmoudi; Sassan Rezaie; Roshanak Daie Ghazvini; Seyed Jamal Hashemi; Hamid Badali; Alireza Foroumadi; Kambiz Diba; Anuradha Chowdhary; Jacques F Meis; Sadegh Khodavaisy
Journal:  Mycopathologia       Date:  2019-08-10       Impact factor: 2.574

8.  Novel Cell-Killing Mechanisms of Hydroxyurea and the Implication toward Combination Therapy for the Treatment of Fungal Infections.

Authors:  Amanpreet Singh; Ameeta Agarwal; Yong-Jie Xu
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 9.  Structure-guided approaches to targeting stress responses in human fungal pathogens.

Authors:  Emmanuelle V LeBlanc; Elizabeth J Polvi; Amanda O Veri; Gilbert G Privé; Leah E Cowen
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

10.  Dysfunction of Prohibitin 2 Results in Reduced Susceptibility to Multiple Antifungal Drugs via Activation of the Oxidative Stress-Responsive Transcription Factor Pap1 in Fission Yeast.

Authors:  Qiannan Liu; Fan Yao; Guanglie Jiang; Min Xu; Si Chen; Lina Zhou; Norihiro Sakamoto; Takayoshi Kuno; Yue Fang
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.